Table 1.
Immune checkpoint inhibitors approved by the FDA for the treatment of different cancer types
| Drug name | Drug target | Cancer types |
|---|---|---|
| Pembrolizumab | PD-1 | Advanced (unresectable or metastatic) melanoma |
| Advanced non-small cell lung cancer | ||
| Recurrent or metastatic head and neck squamous cell carcinoma | ||
| Locally advanced or metastatic urothelial carcinoma | ||
| Classical Hodgkin’s lymphoma | ||
| Recurrent or metastatic gastric or gastroesophageal junction cancer | ||
| Solid tumor with high microsatellite instability or mismatched repair deficiency | ||
| Nivolumab | PD-1 | Unresectable or metastatic melanoma |
| Adjuvant treatment of melanoma patients with lymph node involvement who have undergone complete resection | ||
| Metastatic non-small cell lung cancer | ||
| Advanced renal cell carcinoma | ||
| Classical Hodgkin’s lymphoma | ||
| Recurrent or metastatic head and neck squamous cell carcinoma | ||
| Locally advanced or metastatic urothelial carcinoma | ||
| Avelumab | PD-L1 | Metastatic merkel cell carcinomaa |
| Locally advanced or metastatic urothelial carcinomaa | ||
| Durvalumab | PD-L1 | Locally advanced or metastatic urothelial carcinomaa |
| Locally advanced non small cell lung cancerb | ||
| Atezolizumab | PD-L1 | Locally advanced or metastatic urothelial carcinomaa |
| Metastatic non-small cell lung cancer | ||
| Ipilimumab | CTLA-4 | Unresectable or metastatic melanoma |
| Small cell lung cancer |
aAccelerated approval based on objective response rate and duration of response. Continued approval may depend on further studies and specified disease states
bOn patients who have not progressed following chemotherapy